ALIREZA SEDAGHAT NAMINI M.D.
Prescription History 1124331095
Radiology - Neuroradiology in Van Nuys, CA

Active since July 21, 2010PECOS EnrolledAccepts Medicare Assignment
85/100
CMS Quality Rating
6815 NOBLE AVE, VAN NUYS, CA 91405(818) 901-6600 Get Directions

NPPES record last updated: January 5, 2023. Verified against the NPPES registry weekly; last sync: October 25, 2026.

Record update history: Jan 5, 2023, Oct 21, 2020, Aug 10, 2017 (3 updates tracked since 2017).

Medicare Part D Prescription History

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ALIREZA SEDAGHAT NAMINI M.D., an active Neuroradiology specialist practicing in Van Nuys, CA. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 11 documented patient claims. Among these therapy options, the most frequently utilized medication is Ozempic, which accounts for 11 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.

1
Medication
11
Total Claims
11
30-Day Fills
Ozempic
Most Prescribed · 11 claims
View details
1 medication · 2024 Medicare Part D
Medicare Part D medications prescribed by ALIREZA SEDAGHAT NAMINI M.D. in 2024, with prescription volumes, average cost per fill, and CA state comparisons
Medication Prescriptions (2024)Rx (2024) Avg Cost per FillCost / Fill Vs. Other CA PrescribersVs. CA Avg
OzempicSemaglutide11$989.89▼ below CA avg▼ Less than typical

About Ozempic: Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Show more ▾

Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment. A glucagon-like peptide and GLP-1 agonist used to enhance glycemic control of TYPE 2 DIABETES MELLITUS, and for OBESITY MANAGEMENT.

In 2024, this provider wrote 11 Medicare prescriptions for Ozempic, about 20% of the volume of the typical California prescriber of this medication (56.4). Medicare paid an average of $989.89 per fill, versus $1,102.15 statewide.

How often this provider prescribes it

This provider
11
CA average
56.4

This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference.

What Medicare paid per fill

This provider
$989.89
CA average
$1,102.15

This provider's average cost per fill is below the CA average for this medication.

11
30-Day Fills
standardized to 30-day supplies
308
Days of Medication
total across all patients in 2024
No medications match the current filters.
▲ More than typical≈ Typical▼ Less than typical= prescription volume vs the average CA prescriber of the same medication; volume reflects practice size as well as clinical preference.Green cost= below the CA average cost per fill.

About this data. The prescription history for ALIREZA SEDAGHAT NAMINI M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Neuroradiology prescribing approach at this Van Nuys, CA practice.

Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among CA prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.

About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.